2 / 7
Page 15
Notes:
allied
academies
Microbiology: Current Research
Volume 2
International Conference on
Emerging Diseases, Outbreaks & Case Studies
&
16
th
Annual Meeting on
March 28-29, 2018 | Orlando, USA
Influenza
H
epatocellular carcinoma (HCC) is the most common
primary liver malignancy, over 600,000 cases annually
world-wide. HCC pathogenesis is driven by a complex
product of a chronic inflammatory state generated by liver
chronic liver injury and proliferative signals triggered in the
setting of injury, repair and regeneration. Hepatitis C virus
and/or Hepatitis B virus infection is associated with 5 year
cumulative HCC risk of 30%/17% in Asia/Western nations for
HCV and 15/10% in Asian/Western countries respectively.
Primary biliary cirrhosis, or cirrhosis from alcohol, hereditary
hemochromatosis have five year cumulative risk of HCC
of only 4%. While Cirrhosis of the liver is a major driver
in the pathogenesis of HCC, chronic HCV or HBV infection
independently contribute to tumor promotion due to direct
proliferative stimuli from hepatitis virus. The result is a
host environment in which there is perpetual activation of
inflammatory responses which may lead in some cases to
abnormal cell proliferation or inappropriate persistence of
activation of inflammatory states culminating in malignancy.
The erradication of infection by HBV or HCV virus results
in statistically signficant reduction in HCC incidence in
patients with cirrhosis. Novel anti-viral therapies for HCV
clearance have an increasingly prominent role in cirrhosis
management, but the role for anti-viral therapy in patients
with overt HCC requires additional clarity.
Speaker Biography
Natalyn N Hawk has obtained her MD and PhD from Brown University in Providence,
Rhode Island, in collaboration with the Molecular Pathology Graduate program at MD,
Anderson Cancer Center in Houston, Texas. She has completed her Residency Training
in Internal Medicine at Johns Hopkins Bayview Medical Center in Baltimore, MD. She
has completed Fellowship Training in Hematology and Medical Oncology at Emory
University as well as a Post-graduate Research Fellowship at Emory Winship Cancer
Institute. She is an Assistant Professor of Hematology and Medical Oncology at Emory
University and is a Member of the Gastrointestinal Oncology Working Group of Emory
Winship Cancer Institute. She is also a Member of the Discovery and Developmental
Therapeutics Research Program at Winship Cancer Institute of Emory University.
e:
nhawk@emory.eduThe impact of HCV or HBV clearance on HCC incidence or progression
Natalyn N Hawk
Emory University, USA